KiOmed Pharma

Founded in Liege in 2014, KiOmed Pharma develops injectable medical devices based on CM-chitosan, a biocompatible polysaccharide derivative. The company's lead product targets osteoarthritis, a condition affecting hundreds of millions of people globally and representing a major burden on healthcare systems.

CM-chitosan offers a biologically derived alternative to the synthetic hyaluronic acid injections commonly used for joint lubrication in osteoarthritis treatment. KiOmed's devices have been administered to over 35,000 patients, and the company has secured approval from the Chinese FDA (NMPA), opening access to one of the world's largest markets for this indication.

In 2025, KiOmed raised EUR 18M to support commercial scale-up across European and Asian markets. The company is part of the Liege life sciences cluster, which also includes university spin-offs from the University of Liege.